Coloplast A/S (COLO-B) reported earnings on 2026-08-18. The company posted quarterly revenue growth of +2.2% year over year, a modest top-line gain for a healthcare name that carries a trailing P/E of 46.1 and a forward P/E of 16.5. The most recent quarter on record (Q1 FY2026) came in with a miss of -1.0% versus analyst expectations.
The ACCE score for COLO-B currently sits at 48 out of 100. Breaking that down: Quality leads the scorecard at 70, Growth comes in at 55, Value at 51, and Momentum trails significantly at 17. That Momentum reading reflects a rough stretch for the stock — COLO-B has returned -34.9% over the past year.
On valuation, the six-model fair value estimate stands at $142.72, which represents a -64.4% gap versus the current price of $401.00 (as of 2026-07-10). That is a wide discount implied by the model composite, and it weighs heavily on the overall ACCE score despite the relatively solid Quality and Value sub-scores.
Recibe el resumen semanal de ACCE
Rentabilidad de índices, repaso de selecciones, movimientos de puntuación, cada domingo. Sin relleno.
The analyst consensus target is $462.29, sitting above the current price and pointing in the opposite direction from the fair-value model output. That divergence is worth noting.
What it means
The Quality score of 70 has some backing in the fundamentals. Return on equity is +14.1%, net margin is +7.5%, FCF yield is +4.2%, and earnings quality is rated strong. These are not the numbers of a structurally broken business. The problem, at least as the ACCE model sees it, is that the current price does not reflect those fundamentals at a reasonable multiple.
The dividend yield of +5.4% adds some income support, and with a market cap of $97.11B, COLO-B is not a small or illiquid name. But the Momentum score of 17 signals that price action has been working against holders, consistent with that -34.9% one-year return.
We do not have verified EPS growth figures for this reporting period, and we have no guidance commentary to reference. For the latest earnings-per-share data and any forward outlook from management, visit the live COLO-B page at acceinvestments.com/stocks/COLO-B.
The next catalyst to watch is whether revenue growth can accelerate beyond the current +2.2% pace, which would give the Growth score of 55 room to move higher and potentially close some of the gap between the fair-value estimate and the current price.
See the full picture, free
ACCE scores thousands of stocks across six valuation models, with fair value, conviction and the full thesis on every name. Start free, no card required.
